

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1. NAME OF THE MEDICINAL PRODUCT

REKAMBYS®

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

#### 2 mL vial

Each vial contains 600 mg rilpivirine

#### 3 mL vial

Each vial contains 900 mg rilpivirine

For the full list of excipients, see section 6.1.

### 3. PHARMACEUTICAL FORM

Prolonged-release suspension for injection.  
White to off-white suspension.

### 4. CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

REKAMBYS is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class (see sections 4.2, 4.4 and 5.1).

#### 4.2 Posology and method of administration

Therapy should be prescribed by a physician experienced in the management of HIV infection. Each injection should be administered by a healthcare professional.

**Prior to starting REKAMBYS, the healthcare professional should carefully select patients who agree to the required injection schedule and counsel patients about the importance of adherence to scheduled dosing visits to help maintain viral suppression and reduce the risk of viral rebound and potential development of resistance associated with missed doses.**

**Following discontinuation of REKAMBYS in combination with cabotegravir injection, it is essential to adopt an alternative, fully suppressive antiretroviral regimen no later than one month after the last every 1 month injection of REKAMBYS or two months after the last every 2 months injection of REKAMBYS (see section 4.4).**

The prescribing information for cabotegravir injection should be consulted for recommended dosing.

#### Posology

##### *Oral lead-in*

Prior to the initiation of REKAMBYS, rilpivirine oral tablets, together with cabotegravir oral tablets, should be taken for approximately 1 month (at least 28 days) to assess tolerability to rilpivirine and cabotegravir (see section 4.4). One rilpivirine 25-mg tablet should be taken with a meal with one cabotegravir 30-mg tablet once daily.

##### *Every 1 month dosing*

*Initiation injection (900 mg corresponding to 3 mL)*

On the final day of oral lead-in, the recommended initiation injection dose of rilpivirine in adults is a single 900 mg intramuscular injection.

*Continuation injection (600 mg corresponding to 2 mL)*

After the initiation injection, the recommended continuation injection dose of rilpivirine in adults is a single 600 mg monthly intramuscular injection. Patients may be given injections up to 7 days before or after the date of the monthly injection schedule.

**Table 1: Recommended oral lead-in and monthly dosing schedule in adult patients**

Medicinal Product	Oral Lead-In	IM Initiation injections	IM Continuation injections
	During month 1 (at least 28 days)	At month 2	month 3 onwards
Rilpivirine	25 mg once daily	900 mg	600 mg monthly
Cabotegravir	30 mg once daily	600 mg	400 mg monthly

IM=Intramuscular injection.

*Every 2 months dosing*

*Initiation Injections –1 month apart (900 mg corresponding to 3 mL)*

On the final day of oral lead-in, the recommended initial rilpivirine injection dose in adults is a single 900 mg intramuscular injection (month 2).

One month later (month 3), a second 900 mg intramuscular injection should be administered. Patients may be given the second 900 mg injection up to 7 days before or after the scheduled dosing date.

*Continuation Injections – 2 months apart (900 mg corresponding to 3 mL)*

After the initiation injections, the recommended rilpivirine continuation injection dose in adults is a single 900 mg intramuscular injection administered every 2 months beginning at month 5. Patients may be given injections up to 7 days before or after the date of the every 2 months injection schedule.

**Table 2: Recommended oral lead-in and every 2 months dosing schedule in adult patients**

Medicinal Product	Oral Lead-In	IM Initiation injections	IM Continuation injections
	During month 1 (at least 28 days)	At month 2 and month 3	month 5 onwards
Rilpivirine	25 mg once daily	900 mg monthly	900 mg every 2 months
Cabotegravir	30 mg once daily	600 mg monthly	600 mg every 2 months

*Dosing Recommendations When Switching From Monthly to Every 2 Months Injections*

Patients switching from a monthly continuation injection schedule to an every 2 months continuation injection schedule should receive a single 900 mg intramuscular injection of REKAMBYS one month after the last 600 mg REKAMBYS continuation injection dose and then 900 mg every 2 months thereafter.

*Dosing Recommendations When Switching From Every 2 Months to Monthly Injections*

Patients switching from an every 2 months continuation injection schedule to a monthly continuation injection schedule should receive a single 600 mg intramuscular injection of REKAMBYS two months after the last 900 mg REKAMBYS continuation injection dose and then 600 mg monthly thereafter.

*Missed doses*

Patients who miss an injection visit should be clinically reassessed to ensure resumption of therapy is appropriate. See Table 3 and 4 for dosing recommendations after a missed injection.

*Missed every 1 month injection (Oral Dosing to Replace Up to 2 Consecutive Monthly Injections)*

If a patient plans to miss a scheduled injection by more than 7 days, daily oral therapy (one rilpivirine

tablet [25 mg] and one cabotegravir tablet [30 mg]) may be used to replace up to 2 consecutive monthly injection visits. The first dose of oral therapy should be taken 1 month ( $\pm$  7 days) after the last injection doses of REKAMBYS and cabotegravir. Injection dosing should be resumed on the day oral dosing completes, as recommended in Table 3.

In case more than two months need to be covered for, i.e., missing more than two monthly injections, an alternative oral regimen should be initiated one month ( $\pm$  7 days) after the final injection of REKAMBYS.

**Table 3: REKAMBYS dosing recommendations after missed injections or oral therapy for patients on monthly injection dosing**

Time since last injection	Recommendation
<b><math>\leq</math> 2 months:</b>	Continue with the monthly 600 mg injection schedule as soon as possible.
<b>&gt; 2 months:</b>	Re-initiate the patient on the 900 mg dose, and then continue to follow the monthly 600 mg injection schedule.

#### Missed every 2 months injection (Oral Dosing to Replace 1 Every 2 Months Injection)

If a patient plans to miss a scheduled injection visit by more than 7 days, daily oral therapy (one rilpivirine tablet [25 mg] and one cabotegravir tablet [30 mg]) may be used to replace one ‘every 2 months’ injection visit. The first dose of oral therapy should be taken approximately two months ( $\pm$ 7 days) after the last injection doses of REKAMBYS and cabotegravir. Injection dosing should be resumed on the day oral dosing completes, as recommended in Table 4.

In case more than two months need to be covered for, i.e., missing more than one ‘every 2 months’ injection, an alternative oral regimen should be initiated two months ( $\pm$  7 days) after the final injection of REKAMBYS.

**Table 4: REKAMBYS dosing recommendations after missed injections or oral therapy for patients on every 2 months injection dosing**

Missed Injection Visit	Time since last injection	Recommendation (all injections are 3 mL)
<b>Injection 2 (month 3)</b>	<b><math>\leq</math> 2 months</b>	Continue with the 900 mg injection as soon as possible and continue with every 2 months injection schedule.
	<b>&gt; 2 months</b>	Re-initiate the patient on the 900 mg dose, followed by a second 900 mg initiation injection one month later. Then follow the every 2 months injection schedule.
<b>Injection 3 or later (month 5 onwards)</b>	<b><math>\leq</math> 3 months</b>	Continue with the 900 mg injection as soon as possible and continue with every 2 months injection schedule.
	<b>&gt; 3 months</b>	Re-initiate the patient on the 900 mg dose, followed by a second 900 mg initiation injection one month later. Then follow the every 2 months injection schedule.

#### Special populations

##### *Elderly*

There is limited information regarding the use of REKAMBYS in patients > 65 years of age. No dose adjustment of REKAMBYS is required in older patients (see sections 5.1 and 5.2).

##### *Renal impairment*

No dose adjustment is required in patients with mild or moderate renal impairment. In patients with severe renal impairment or end stage renal disease, the combination of REKAMBYS with a strong CYP3A inhibitor should only be used if the benefit outweighs the risk. Subjects with estimated creatinine clearance < 50 mL/min/1.73 m<sup>2</sup> were not included in the Phase 3 studies. No data are available in subjects receiving dialysis although differences in pharmacokinetics are not expected in this population (see section 5.2).

##### *Hepatic impairment*

No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh score A or B), but caution is advised in patients with moderate hepatic impairment. No data are

available in patients with severe hepatic impairment (Child-Pugh score C); therefore REKAMBYS is not recommended in these patients (see section 5.2).

#### *Paediatric population*

The safety and efficacy of REKAMBYS in children and adolescents aged < 18 years have not been established. No data are available.

#### Method of administration

For intramuscular use.

Care should be taken to avoid inadvertent injection of REKAMBYS into a blood vessel. The suspension should be injected slowly (see section 4.4).

Prior to administration, the REKAMBYS vial should be brought to room temperature.

REKAMBYS should be administered by a healthcare professional. For instructions on administration, see “Instructions for Use” in the package leaflet.

REKAMBYS should always be co-administered with a cabotegravir injection. REKAMBYS and cabotegravir injections should be administered at separate gluteal injection sites during the same visit. The order of injections is not important.

When administering REKAMBYS, the healthcare professional should take into consideration the body mass index (BMI) of the patient to ensure that the needle length is sufficient to reach the gluteus muscle. The pack contains 1 injection needle (see section 6.5).

The vial should be held firmly and shaken vigorously for a full 10 seconds. The vial should be inverted and the resuspension should be checked. It should look uniform. If the suspension is not uniform, the vial should be shaken again. It is normal to see small air bubbles.

Injections must be administered to the ventrogluteal (recommended) or the dorsogluteal sites.

### **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

REKAMBYS must not be co-administered with the following medicinal products, as significant decreases in rilpivirine plasma concentrations may occur (due to CYP3A enzyme induction), which may result in loss of therapeutic effect of REKAMBYS (see section 4.5):

- the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, phenytoin
- the antimycobacterials rifabutin, rifampicin, rifapentine
- the systemic glucocorticoid dexamethasone, except as a single dose treatment
- St John’s wort (*Hypericum perforatum*).

### **4.4 Special warnings and precautions for use**

#### **Risk of resistance following treatment discontinuation**

**To minimise the risk of developing viral resistance it is essential to adopt an alternative, fully suppressive antiretroviral regimen no later than one month after the last every 1 month injection of REKAMBYS or two months after the last every 2 months injection of REKAMBYS.**

If virologic failure is suspected, an alternative regimen should be adopted as soon as possible.

#### Long-acting properties of rilpivirine injection

Residual concentrations of rilpivirine may remain in the systemic circulation of patients for prolonged periods (up to 4 years in some patients) and should be considered upon discontinuation of REKAMBYS (see sections 4.5, 4.6, 4.7, 4.9).

#### Baseline factors associated with virological failure

Before starting the regimen, it should be taken into account that multivariable analyses indicate that a combination of at least 2 of the following baseline factors may be associated with an increased risk of virological failure: archived rilpivirine resistance mutations, HIV-1 subtype A6/A1, or BMI  $\geq$  30 kg/m<sup>2</sup>. Available data suggest that virologic failure occurs more often when these patients are treated according to the every 2 month dosing schedule as compared to the monthly dosing regimen. In patients with an incomplete or uncertain treatment history without pre-treatment resistance analyses, caution is warranted in the presence of either BMI  $\geq$  30 kg/m<sup>2</sup> or HIV-1 subtype A6/A1 (see section 5.1).

#### Post-injection reactions

Accidental intravenous administration may result in AEs due to temporarily high plasma concentrations. In clinical studies, serious post-injection reactions were reported within minutes after the injection of rilpivirine. These events included symptoms such as dyspnoea, bronchospasm, agitation, abdominal cramping, rash/urticaria, dizziness, flushing, sweating, oral numbness, changes in blood pressure, and pain (e.g., back and chest). These events were very rare and began to resolve within minutes after the injection. Some of the patients received symptomatic treatment, at the discretion of the treating physician.

Carefully follow the Instructions for Use when preparing and administering REKAMBYS (see section 4.2). Observe patients briefly (approximately 10 minutes) after the injection. If a patient experiences a post-injection reaction, monitor and treat as clinically indicated.

#### Cardiovascular

REKAMBYS should be used with caution when co-administered with a medicinal product with a known risk of Torsade de Pointes. At supra-therapeutic doses (75 and 300 mg once daily), oral rilpivirine has been associated with prolongation of the QTc interval of the electrocardiogram (ECG) (see sections 4.5, 4.8 and 5.2). Oral rilpivirine at the recommended dose of 25 mg once daily is not associated with a clinically relevant effect on QTc. Plasma rilpivirine concentrations after REKAMBYS injections are comparable to those during such oral rilpivirine therapy.

#### HBV/HCV co-infection

Patients with hepatitis B co-infection were excluded from studies with REKAMBYS. It is not recommended to initiate REKAMBYS in patients with hepatitis B co-infection. In patients co-infected with hepatitis B receiving oral rilpivirine, the incidence of hepatic enzyme elevation was higher than in patients receiving oral rilpivirine who were not hepatitis B co-infected. Physicians should refer to current treatment guidelines for the management of HIV infection in patients co-infected with hepatitis B virus.

Limited data is available in patients with hepatitis C co-infection. In patients co-infected with hepatitis C receiving oral rilpivirine, the incidence of hepatic enzyme elevation was higher than in patients receiving oral rilpivirine who were not hepatitis C co-infected. The pharmacokinetic exposure of oral and injectable rilpivirine in co-infected patients was comparable to that in patients without hepatitis C co-infection. Monitoring of liver function is recommended in patients with hepatitis C co-infection.

#### Interactions with other medicinal products

REKAMBYS should not be administered with other antiretroviral medicinal products, except for cabotegravir injection for the treatment of HIV-1 infection (see section 4.5).

#### Pregnancy

There are limited data of REKAMBYS in pregnant women. REKAMBYS is not recommended during pregnancy unless the expected benefit justifies the potential risk. Lower exposures of oral rilpivirine were observed when rilpivirine 25 mg once daily was taken during pregnancy. In the Phase 3 studies with oral rilpivirine, lower rilpivirine exposure, similar to that seen during pregnancy, has been associated with an increased risk of virological failure, therefore viral load should be monitored closely. Alternatively, switching to another ART regimen could be considered (see sections 4.6, 5.1 and 5.2).

#### Immune reactivation syndrome

In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and *Pneumocystis jirovecii* pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary. Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution, however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.

#### Opportunistic infections

Patients should be advised that REKAMBYS or any other antiretroviral therapy does not cure HIV infection and that they may still develop opportunistic infections and other complications of HIV infection. Therefore, patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.

#### Excipients

This medicine contains less than 1 mmol sodium (23 mg) per injection, that is to say essentially 'sodium-free'.

### **4.5 Interaction with other medicinal products and other forms of interaction**

REKAMBYS, in combination with cabotegravir injection, is intended for use as a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral medicinal products for the treatment of HIV-1. Therefore, information regarding drug-drug interactions with other antiretroviral medicinal products is not provided. From a drug interaction perspective, there are no limitations on the use of other antiretroviral medicinal products after discontinuing REKAMBYS.

For the oral lead-in rilpivirine treatment and in case missed doses are replaced by oral rilpivirine treatment, refer to the oral rilpivirine tablet SmPC for information about drug interactions.

#### Medicinal products that affect rilpivirine exposure

Rilpivirine is primarily metabolised by cytochrome P450 (CYP)3A. Medicinal products that induce or inhibit CYP3A may thus affect the clearance of rilpivirine (see section 5.2). Co-administration of rilpivirine and medicinal products that induce CYP3A has been observed to decrease the plasma concentrations of rilpivirine, which could reduce the therapeutic effect of rilpivirine.

Co-administration of rilpivirine and medicinal products that inhibit CYP3A has been observed to increase the plasma concentrations of rilpivirine.

When using oral rilpivirine, proton pump inhibitors are contraindicated (see rilpivirine tablet SmPC, section 4.3).

#### Medicinal products that are affected by the use of rilpivirine

Rilpivirine is not likely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.

Rilpivirine inhibits P-glycoprotein *in vitro* (IC<sub>50</sub> is 9.2 µM). In a clinical study, oral rilpivirine (25 mg once daily) did not significantly affect the pharmacokinetics of digoxin.

Rilpivirine is an *in vitro* inhibitor of the transporter MATE-2K with an IC<sub>50</sub> of < 2.7 nM. The clinical implications of this finding are currently unknown.

### Interaction table

Selected established and theoretical interactions between rilpivirine and co-administered medicinal products are listed in Table 5 and are based on the studies conducted with oral rilpivirine or are potential drug interactions that may occur (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, not applicable as “NA”, confidence interval as “CI”).

**Table 5: Interactions and dose recommendations with other medicinal products**

Medicinal products by therapeutic areas	Interaction Geometric mean change (%)Ω	Recommendations concerning co-administration
<b>ANTIVIRAL AGENTS</b>		
Cabotegravir	cabotegravir AUC ↔ cabotegravir C <sub>min</sub> ↔ cabotegravir C <sub>max</sub> ↔ rilpivirine AUC ↔ rilpivirine C <sub>min</sub> ↓ 8% rilpivirine C <sub>max</sub> ↔	No dose adjustment is required.
Ribavirin	Not studied. No clinically relevant drug-drug interaction is expected.	No dose adjustment is required.
<b>ANTICONVULSANTS</b>		
Carbamazepine Oxcarbazepine Phenobarbital Phenytoin	Not studied. Significant decreases in rilpivirine plasma concentrations are expected.  (induction of CYP3A enzymes)	Rilpivirine must not be used in combination with these anticonvulsants as co-administration may result in loss of therapeutic effect of rilpivirine (see section 4.3).
<b>AZOLE ANTIFUNGAL AGENTS</b>		
Ketoconazole*# 400 mg once daily	ketoconazole AUC ↓ 24% ketoconazole C <sub>min</sub> ↓ 66% ketoconazole C <sub>max</sub> ↔  (induction of CYP3A due to high rilpivirine dose in the study)  rilpivirine AUC ↑ 49% rilpivirine C <sub>min</sub> ↑ 76% rilpivirine C <sub>max</sub> ↑ 30%  (inhibition of CYP3A enzymes)	No dose adjustment is required.

Fluconazole Itraconazole Posaconazole Voriconazole	Not studied. Concomitant use of REKAMBYS with azole antifungal agents may cause an increase in the plasma concentrations of rilpivirine.  (inhibition of CYP3A enzymes)	No dose adjustment is required.
<b>ANTIMYCOBACTERIALS</b>		
Rifabutin*# 300 mg once daily  300 mg once daily (+ 25 mg once daily rilpivirine)  300 mg once daily (+ 50 mg once daily rilpivirine)	rifabutin AUC ↔ rifabutin C <sub>min</sub> ↔ rifabutin C <sub>max</sub> ↔ 25-O-desacetyl-rifabutin AUC ↔ 25-O-desacetyl-rifabutin C <sub>min</sub> ↔ 25-O-desacetyl-rifabutin C <sub>max</sub> ↔  rilpivirine AUC ↓ 42% rilpivirine C <sub>min</sub> ↓ 48% rilpivirine C <sub>max</sub> ↓ 31%  rilpivirine AUC ↑ 16%* rilpivirine C <sub>min</sub> ↔* rilpivirine C <sub>max</sub> ↑ 43%*  * compared to 25 mg once daily rilpivirine alone  (induction of CYP3A enzymes)	REKAMBYS must not be used in combination with rifabutin as specific dosing recommendations have not been established. Co-administration is likely to result in loss of therapeutic effect of rilpivirine (see section 4.3).
Rifampicin*# 600 mg once daily	rifampicin AUC ↔ rifampicin C <sub>min</sub> NA rifampicin C <sub>max</sub> ↔ 25-desacetyl-rifampicin AUC ↓ 9% 25-desacetyl-rifampicin C <sub>min</sub> NA 25-desacetyl-rifampicin C <sub>max</sub> ↔ rilpivirine AUC ↓ 80% rilpivirine C <sub>min</sub> ↓ 89% rilpivirine C <sub>max</sub> ↓ 69%  (induction of CYP3A enzymes)	Rilpivirine must not be used in combination with rifampicin as co-administration is likely to result in loss of therapeutic effect of rilpivirine (see section 4.3).
Rifapentine	Not studied. Significant decreases in rilpivirine plasma concentrations are expected.  (induction of CYP3A enzymes)	Rilpivirine must not be used in combination with rifapentine as co-administration is likely to result in loss of therapeutic effect of rilpivirine (see section 4.3).
<b>MACROLIDE ANTIBIOTICS</b>		
Clarithromycin Erythromycin	Not studied. Increased exposure of rilpivirine is expected.  (inhibition of CYP3A enzymes)	Where possible, alternatives such as azithromycin should be considered.
<b>GLUCOCORTICOIDS OR CORTICOSTEROIDS</b>		
Dexamethasone (systemic, except for single dose use)	Not studied. Dose dependent decreases in rilpivirine plasma concentrations are expected.  (induction of CYP3A enzymes)	Rilpivirine should not be used in combination with systemic dexamethasone (except as a single dose) as co-administration may result in loss of therapeutic effect of rilpivirine (see section 4.3). Alternatives should be considered, particularly for long-term use.



<b>NARCOTIC ANALGESICS</b>		
Methadone* 60- 100 mg once daily, individualised dose	R(-) methadone AUC ↓ 16% R(-) methadone Cmin ↓ 22% R(-) methadone Cmax ↓ 14% rilpivirine AUC ↔* rilpivirine Cmin ↔* rilpivirine Cmax ↔* * based on historic controls	No dose adjustments are required when initiating co-administration of methadone with rilpivirine. However, clinical monitoring is recommended as methadone maintenance therapy may need to be adjusted in some patients.
<b>ANTIARRHYTHMICS</b>		
Digoxin*	digoxin AUC ↔ digoxin Cmin NA digoxin Cmax ↔	No dose adjustment is required.
<b>ANTIDIABETICS</b>		
Metformin*	metformin AUC ↔ metformin Cmin NA metformin Cmax ↔	No dose adjustment is required.
<b>HERBAL PRODUCTS</b>		
St John's wort (Hypericum perforatum)	Not studied. Significant decreases in rilpivirine plasma concentrations are expected.  (induction of CYP3A enzymes)	Rilpivirine must not be used in combination with products containing St John's wort as co-administration may result in loss of therapeutic effect of rilpivirine (see section 4.3).
<b>ANALGESICS</b>		
Paracetamol*## 500 mg single dose	paracetamol AUC ↔ paracetamol Cmin NA paracetamol Cmax ↔ rilpivirine AUC ↔ rilpivirine Cmin ↑ 26% rilpivirine Cmax ↔	No dose adjustment is required.
<b>ORAL CONTRACEPTIVES</b>		
Ethinylestradiol* 0.035 mg once daily Norethindrone* 1 mg once daily	ethinylestradiol AUC ↔ ethinylestradiol Cmin ↔ ethinylestradiol Cmax ↑ 17% norethindrone AUC ↔ norethindrone Cmin ↔ norethindrone Cmax ↔ rilpivirine AUC ↔* rilpivirine Cmin ↔* rilpivirine Cmax ↔* * based on historic controls	No dose adjustment is required.
<b>HMG CO-A REDUCTASE INHIBITORS</b>		
Atorvastatin*## 40 mg once daily	atorvastatin AUC ↔ atorvastatin Cmin ↓ 15% atorvastatin Cmax ↑ 35% rilpivirine AUC ↔ rilpivirine Cmin ↔ rilpivirine Cmax ↓ 9%	No dose adjustment is required.
<b>PHOSPHODIESTERASE TYPE 5 (PDE-5) INHIBITORS</b>		
Sildenafil*## 50 mg single dose	sildenafil AUC ↔ sildenafil Cmin NA sildenafil Cmax ↔ rilpivirine AUC ↔ rilpivirine Cmin ↔ rilpivirine Cmax ↔	No dose adjustment is required.
Vardenafil Tadalafil	Not studied.	No dose adjustment is required.

Ω % increase/decrease based on Drug-Drug Interaction studies with oral rilpivirine

\* The interaction between rilpivirine and the medicinal product was evaluated in a clinical study. All other drug-drug interactions shown are predicted.

# This interaction study has been performed with a dose higher than the recommended dose for rilpivirine assessing the maximal effect on the co-administered medicinal product. The dosing recommendation is applicable to the recommended dose of rilpivirine of 25 mg once daily.

#### QT prolonging medicinal products

Oral rilpivirine at the recommended dose of 25 mg once daily is not associated with a clinically relevant effect on QTc. Rilpivirine plasma concentrations after REKAMBYS injections at the recommended dose of 600 mg monthly or 900 mg every 2 months, are comparable to those achieved with oral rilpivirine at a dose of 25 mg qd. In a study of healthy subjects, supratherapeutic doses of oral rilpivirine (75 mg once daily and 300 mg once daily) have been shown to prolong the QTc interval of the ECG (see section 5.1). REKAMBYS should be used with caution when co-administered with a medicinal product with a known risk of Torsade de Pointes (see section 4.4).

### **4.6 Fertility, pregnancy and lactation**

#### Pregnancy

The effect of REKAMBYS on human pregnancy is unknown.

A moderate amount of data with oral rilpivirine in pregnant women (between 300-1000 pregnancy outcomes) indicate no malformative or foetal/neonatal toxicity of rilpivirine.

A study of 19 pregnant women treated with oral rilpivirine in combination with a background regimen during the second and third trimesters, and postpartum, showed lower exposures of oral rilpivirine during pregnancy, therefore viral load should be monitored closely if REKAMBYS is used during pregnancy.

Animal studies do not indicate reproductive toxicity (see section 5.3).

REKAMBYS is not recommended during pregnancy unless the expected benefit justifies the potential risk.

An alternative oral regimen should be considered in line with current treatment guidelines. After discontinuation of REKAMBYS, rilpivirine may remain in systemic circulation for up to 4 years in some patients (see section 4.4).

#### Breast-feeding

It is expected that rilpivirine will be secreted into human milk based on animal data, although this has not been confirmed in humans. Rilpivirine may be present in human milk for up to 4 years in some patients after discontinuation of REKAMBYS.

In order to avoid transmission of HIV to the infant it is recommended that women living with HIV do not breast-feed.

#### Fertility

No human data on the effect of rilpivirine on fertility are available. No clinically relevant effects on fertility were seen in animal studies (see section 5.3).

### **4.7 Effects on ability to drive and use machines**

Patients should be informed that fatigue, dizziness and somnolence could occur when treated with REKAMBYS (see section 4.8).

### **4.8 Undesirable effects**

#### Summary of the safety profile

The most frequently reported ARs from every 1-month dosing studies were injection site reactions (up to 84%), headache (up to 12%) and pyrexia (10%).

The most frequently reported ARs from every 2 months dosing were injection site reactions (76%), headache (7%) and pyrexia (7%).

#### Tabulated summary of adverse reactions

The ARs identified for rilpivirine and/or cabotegravir are listed by system organ class (SOC) and frequency (see Table 6). Frequencies are defined as very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ) and uncommon ( $\geq 1/1,000$  to  $< 1/100$ ).

**Table 6: Tabulated summary of adverse reactions<sup>1</sup>**

MedDRA System Organ Class (SOC)	Frequency Category	ARs for rilpivirine + cabotegravir regimen
Blood and lymphatic system disorders	Common	decreased white blood cell count <sup>2</sup> , decreased haemoglobin <sup>2</sup> , decreased platelet count <sup>2</sup>
Immune System Disorders	Uncommon	immune reactivation syndrome <sup>2</sup>
Metabolism and nutrition disorders	Very common	increased total cholesterol (fasted) <sup>2</sup> , increased LDL cholesterol (fasted) <sup>2</sup>
	Common	decreased appetite <sup>2</sup> , increased triglycerides (fasted) <sup>2</sup>
Psychiatric disorders	Common	depression, anxiety, abnormal dreams, insomnia, sleep disorder <sup>2</sup> , depressed mood <sup>2</sup>
Nervous system disorders	Very common	headache
	Common	dizziness
	Uncommon	somnolence, vasovagal reactions (in response to injections)
Gastrointestinal disorders	Very common	increased pancreatic amylase <sup>2</sup>
	Common	nausea, vomiting, abdominal pain <sup>3</sup> , flatulence, diarrhoea, abdominal discomfort <sup>2</sup> , dry mouth <sup>2</sup> , increased lipase <sup>2</sup>
Hepatobiliary disorders	Uncommon	hepatotoxicity
Skin and subcutaneous tissue disorders	Common	rash <sup>4</sup>
Musculoskeletal and connective tissue disorders	Common	myalgia
General disorders and administrative site conditions	Very common	injection site reactions (pain and discomfort, nodule, induration), pyrexia <sup>5</sup>
	Common	injection site reactions (swelling, erythema, pruritus, bruising, warmth, haematoma), fatigue, asthenia, malaise
	Uncommon	injection site reactions (cellulitis, abscess, anaesthesia, haemorrhage, discolouration)
Investigations	Common	weight increased
	Uncommon	transaminase increased, blood bilirubin increased

<sup>1</sup> The frequency of the identified ARs are based on all reported occurrences of the events and are not limited to those considered at least possibly related by the investigator.

<sup>2</sup> Additional adverse reactions seen with oral rilpivirine in other studies.

<sup>3</sup> Abdominal pain includes the following grouped MedDRA preferred term: abdominal pain, upper abdominal pain.

<sup>4</sup> Rash includes the following grouped MedDRA preferred terms: rash, rash erythematous, rash generalised, rash macular, rash maculo-papular, rash morbilliform, rash papular, rash pruritic.

<sup>5</sup> Pyrexia includes the following grouped MedDRA preferred terms: pyrexia, feeling hot, body temperature increased. The majority of pyrexia events were reported within one week of injections.

#### Description of selected adverse reactions

##### *Local Injection Site Reactions (ISRs)*

Up to 1% of subjects discontinued treatment with rilpivirine and cabotegravir injections because of ISRs.

Injection site reactions were generally mild (Grade 1, 70%-75% of subjects) or moderate (Grade 2, 27%-36% of subjects). 3-4% of subjects experienced severe (Grade 3) ISRs. The median duration of ISR events was 3 days. The percentage of subjects reporting ISRs decreased over time.

#### *Weight increased*

At the Week 48 time point, subjects in Phase 3 Studies FLAIR and ATLAS, who received rilpivirine plus cabotegravir gained a median of 1.5 kg in weight; subjects continuing on their current antiretroviral regimen (CAR) group gained a median of 1.0 kg (pooled analysis).

In the individual studies FLAIR and ATLAS, the median weight gains in the rilpivirine plus cabotegravir arms were 1.3 kg and 1.8 kg respectively, compared to 1.5 kg and 0.3 kg in the CAR arms.

At the 48 week timepoint, in ATLAS-2M the median weight gain in both the monthly and every 2 months rilpivirine+cabotegravir dosing arms was 1.0 kg.

#### *Changes in laboratory chemistry*

Elevated transaminases (ALT/AST) were observed in subjects receiving rilpivirine plus cabotegravir during the clinical studies. These elevations were primarily attributed to acute viral hepatitis. A few subjects on oral rilpivirine plus oral cabotegravir treatment had transaminase elevations attributed to suspected drug-related hepatotoxicity; these changes were reversible upon discontinuation of treatment.

Small, non-progressive increases in total bilirubin (without clinical jaundice) were observed with treatment with rilpivirine plus cabotegravir. These changes are not considered clinically relevant as they likely reflect competition between cabotegravir and unconjugated bilirubin for a common clearance pathway (UGT1A1).

Elevated lipases were observed during clinical trials with rilpivirine plus cabotegravir. Grade 3 and 4 lipase increases occurred at a higher incidence with rilpivirine plus cabotegravir compared with CAR. These elevations were generally asymptomatic and did not lead to rilpivirine plus cabotegravir discontinuation. One case of fatal pancreatitis with Grade 4 lipase and confounding factors (including history of pancreatitis) has been reported in study ATLAS-2M for which the causality to the injection regimen could not be ruled out.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse reactions should be reported to the Ministry of Health according to the National Regulation by using an online form: <https://sideeffects.health.gov.il>.

## **4.9 Overdose**

There is currently limited experience with REKAMBYS overdose. If overdose occurs, the patient should be treated supportively and as clinically indicated, with monitoring of vital signs and ECG (QT interval), as necessary. Since rilpivirine is highly bound to plasma protein, dialysis is unlikely to result in significant removal of the active substance.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antiviral for systemic use, non-nucleoside reverse transcriptase inhibitors, ATC code: J05AG05

#### Mechanism of action

Rilpivirine is a diarylpyrimidine non-nucleoside reverse-transcriptase inhibitor (NNRTI) of HIV-1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases  $\alpha$ ,  $\beta$  and  $\gamma$ .

### Antiviral activity *in vitro*

Rilpivirine exhibited activity against laboratory strains of wild-type HIV-1 in an acutely infected T-cell line with a median EC<sub>50</sub> value for HIV-1/IIIB of 0.73 nM (0.27 ng/mL). Although rilpivirine demonstrated limited *in vitro* activity against HIV-2 with EC<sub>50</sub> values ranging from 2,510 to 10,830 nM (920 to 3,970 ng/mL), treatment of HIV-2 infection with rilpivirine is not recommended in the absence of clinical data.

Rilpivirine also demonstrated antiviral activity against a broad panel of HIV-1 group M (subtype A, B, C, D, F, G, H) primary isolates with EC<sub>50</sub> values ranging from 0.07 to 1.01 nM (0.03 to 0.37 ng/mL) and group O primary isolates with EC<sub>50</sub> values ranging from 2.88 to 8.45 nM (1.06 to 3.10 ng/mL).

### Resistance

Considering all of the available *in vitro* data and *in vivo* data generated with oral rilpivirine in previously untreated patients, the following resistance-associated mutations, when present at baseline, may affect the activity of rilpivirine: K101E, K101P, E138A, E138G, E138K, E138R, E138Q, V179L, Y181C, Y181I, Y181V, Y188L, H221Y, F227C, M230I, M230L, and the combination of L100I and K103N.

### *In cell culture*

Rilpivirine-resistant strains were selected in cell culture starting from wild-type HIV-1 of different origins and subtypes as well as NNRTI resistant HIV-1. The most commonly observed resistance-associated mutations that emerged included L100I, K101E, V108I, E138K, V179F, Y181C, H221Y, F227C and M230I.

### *Virologically suppressed patients:*

The number of subjects who met confirmed virologic failure (CVF) criteria was low across the pooled Phase 3 studies ATLAS and FLAIR. There were 7 CVFs on rilpivirine plus cabotegravir (7/591, 1.2%) and 7 CVFs on current antiretroviral regimen (7/591, 1.2%) through week 48. In the rilpivirine plus cabotegravir group in the pooled analysis, 5/591 (0.8%) subjects had resistance development: 5/591 (0.8%) and 4/591 (0.7%) with resistance-associated mutations to rilpivirine (K101E [n=1], E138A/E/K/T [n=1], E138A [n=1], or E138K [n=2]) and/or cabotegravir (G140R [n=1], Q148R [n=2], or N155H [n=1]), respectively. The 4 CVFs on cabotegravir plus rilpivirine in FLAIR had HIV-1 subtype A1 (n=3) or AG (n=1). One CVF in FLAIR never received an injection. The 3 CVFs on cabotegravir plus rilpivirine in ATLAS had HIV-1 subtype A, A1, or AG. In 2 of these 3 CVFs the rilpivirine resistance-associated mutations observed at failure were also observed at baseline in PBMC HIV-1 DNA.

In the ATLAS-2M study 10 subjects met CVF criteria through week 48: 8/522 (1.5%) in the Q8W arm and 2/523 (0.4%) in the Q4W arm. In the Q8W group 5/522 (1.0%) had resistance development: 4/522 (0.8%) and 5/522 (1.0%) with resistance-associated mutations to rilpivirine (E138A [n=1], E138K [n=1], K101E [n=2], or Y188L [n=1]) and/or cabotegravir (Q148R [n=3] or N155H [n=4]), respectively. In the Q4W group 2/523 (0.4%) had resistance development: 1/523 (0.2%) and 2/523 (0.4%) had rilpivirine (K101E [n=1], M230L [n=1]) and/or cabotegravir (E138K [n=1], Q148R [n=1], or N155H [n=1]) resistance-associated mutations, respectively. At baseline in the Q8W arm, 5 subjects had rilpivirine resistance-associated mutations and 1 of those subjects carried a cabotegravir resistance-associated mutation. Neither subject in the Q4W arm had any rilpivirine or cabotegravir resistance-associated mutation at baseline. The 10 CVFs on cabotegravir plus rilpivirine in ATLAS-2M had HIV-1 subtype A (n=1), A1 (n=2), B (n=4), C (n=2), or Complex (n=1).

### Cross-resistance

#### *Site-directed NNRTI mutant virus*

In a panel of 67 HIV-1 recombinant laboratory strains with one mutation at RT positions associated with NNRTI resistance, including the most commonly found K103N and Y181C, rilpivirine showed

antiviral activity against 64 (96%) of these strains. The single resistance-associated mutations associated with a loss of susceptibility to rilpivirine were: K101P, Y181I and Y181V. The K103N mutation did not result in reduced susceptibility to rilpivirine by itself, but the combination of K103N and L100I resulted in a 7-fold reduced susceptibility to rilpivirine.

#### *Recombinant clinical isolates*

Rilpivirine retained sensitivity (fold change  $\leq$  biological cut-off) against 62% of 4,786 HIV-1 recombinant clinical isolates resistant to efavirenz and/or nevirapine.

#### *Virologically suppressed patients*

In the week 48 analysis of the Phase 3 studies ATLAS and FLAIR, 5/7 CVFs had phenotypic resistance against rilpivirine at failure. Among these 5 patients, phenotypic cross-resistance was observed against efavirenz (n=4), etravirine (n=3), and nevirapine (n=4).

#### Effects on electrocardiogram

No effect on QTcF interval was shown for oral rilpivirine at the recommended dose of 25 mg once daily in a randomised, placebo and active (moxifloxacin 400 mg once daily) controlled crossover study in 60 healthy adults, with 13 measurements over 24 hours at steady-state. Plasma rilpivirine concentrations after REKAMBYS injections are comparable to those achieved with oral rilpivirine at dose of 25 mg qd. REKAMBYS at the recommended dose of 600 mg monthly or 900 mg every 2 months is not associated with a clinically relevant effect on QTc.

When supratherapeutic doses of 75 mg once daily and 300 mg once daily of oral rilpivirine were studied in healthy adults, the maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline correction were 10.7 (15.3) and 23.3 (28.4) ms, respectively. Steady-state administration of oral rilpivirine 75 mg once daily and 300 mg once daily resulted in a mean  $C_{max}$  approximately 4.4-fold and 11.6-fold, respectively, higher than the mean steady-state  $C_{max}$  observed with the recommended 600 mg once monthly dose of REKAMBYS. Steady state administration of oral rilpivirine 75 mg once daily and 300 mg once daily resulted in a mean  $C_{max}$  approximately 4.1-fold and 10.7-fold, respectively, higher than the mean steady state  $C_{max}$  observed with the recommended 900 mg every 2 months dose of REKAMBYS.

#### Clinical efficacy and safety

##### Every 1 month dosing

The efficacy of REKAMBYS plus cabotegravir injection has been evaluated in two Phase 3 randomised, multicentre, active-controlled, parallel-arm, open-label, non-inferiority studies, FLAIR (201584) and ATLAS (201585). The primary analysis was conducted after all subjects completed their week 48 visit or discontinued the study prematurely.

##### Patients virologically suppressed (on prior dolutegravir-based regimen for 20 weeks)

In FLAIR, 629 HIV-1-infected, antiretroviral treatment (ART)-naive subjects received a dolutegravir integrase strand transfer inhibitor (INI) containing regimen for 20 weeks (either dolutegravir/abacavir/lamivudine or dolutegravir + 2 other nucleoside reverse transcriptase inhibitors if subjects were HLA-B\*5701 positive). Subjects who were virologically suppressed (HIV-1 RNA  $<$  50 copies per mL, n=566) were then randomised (1:1) to receive either a rilpivirine plus cabotegravir regimen or remain on the CAR. Subjects randomised to receive the rilpivirine plus cabotegravir regimen, initiated treatment with oral lead-in dosing with a cabotegravir (30 mg) tablet plus a rilpivirine (25 mg) tablet once daily for at least 4 weeks, followed by treatment with cabotegravir injection (month 1: 600 mg, month 2 onwards: 400 mg injection) plus rilpivirine injection (month 1: 900 mg injection, month 2 onwards: 600 mg injection), monthly, for up to 96 weeks.

##### Patients virologically suppressed (stable on prior ART for at least 6 months)

In ATLAS, 616 HIV-1-infected, ART-experienced, virologically-suppressed (for at least 6 months) subjects (HIV-1 RNA  $<$  50 copies per mL) were randomised (1:1) and received either a rilpivirine plus cabotegravir regimen or remained on the CAR. Subjects randomised to receive the rilpivirine plus

cabotegravir regimen initiated treatment with oral lead-in dosing with a cabotegravir (30 mg) tablet plus a rilpivirine (25 mg) tablet once daily for at least 4 weeks, followed by treatment with cabotegravir injection (month 1: 600 mg, month 2 onwards: 400 mg injection) plus rilpivirine injection (month 1: 900 mg injection, month 2 onwards: 600 mg injection), monthly, for an additional 44 weeks. In ATLAS, 50%, 17%, and 33% of subjects received an NNRTI, PI, or INI (respectively) as their baseline third treatment agent class prior to randomisation and this was similar between treatment arms.

### Pooled Phase 3 studies

At baseline, in the pooled analysis, in the rilpivirine plus cabotegravir arm the median age of subjects was 38 years, 27% were female, 27% were non-white, 1% were  $\geq 65$  years and 7% had CD4+ cell count less than 350 cells per  $\text{mm}^3$ ; these characteristics were similar between treatment arms.

The primary endpoint of both studies was the proportion of subjects with plasma HIV-1 RNA  $\geq 50$  copies/mL at week 48 (snapshot algorithm for the ITT-E population).

In a pooled analysis of the two Phase 3 studies, rilpivirine plus cabotegravir was non-inferior to CAR on the proportion of subjects having plasma HIV-1 RNA  $\geq 50$  c/mL (1.9% and 1.7% respectively) at week 48. The adjusted treatment difference between rilpivirine plus cabotegravir and CAR (0.2; 95% CI: -1.4, 1.7) met the non-inferiority criterion (upper bound of the 95% CI below 4%) [See Table 7].

The primary endpoint and other week 48 outcomes, including outcomes by key baseline factors, for FLAIR, ATLAS, and pooled data are shown in Table 7 and Table 8.

**Table 7: Virologic outcomes of randomised treatment in FLAIR and ATLAS at week 48 (Snapshot analysis)**

	FLAIR		ATLAS		Pooled Data	
	RPV+ CAB N=283	CAR N=283	RPV+ CAB N=308	CAR N=308	RPV+ CAB N=591	CAR N=591
<b>HIV-1 RNA <math>\geq 50</math> copies/mL<sup>†</sup></b>	6 (2.1)	7 (2.5)	5 (1.6)	3 (1.0)	11 (1.9)	10 (1.7)
Treatment Difference % (95% CI)*	-0.4 (-2.8, 2.1)		0.7 (-1.2, 2.5)		0.2 (-1.4, 1.7)	
<b>HIV-1 RNA &lt; 50 copies/mL</b>	265 (93.6)	264 (93.3)	285 (92.5)	294 (95.5)	550 (93.1)	558 (94.4)
Treatment Difference % (95% CI)*	0.4 (-3.7, 4.5)		-3.0 (-6.7, 0.7)		-1.4 (-4.1, 1.4)	
<b>No virologic data at week 48 window</b>	12 (4.2)	12 (4.2)	18 (5.8)	11 (3.6)	30 (5.1)	23 (3.9)
<b>Reasons</b>						
Discontinued study/study drug due to adverse event or death	8 (2.8)	2 (0.7)	11 (3.6)	5 (1.6)	19 (3.2)	7 (1.2)
Discontinued study/study drug for other reasons	4 (1.4)	10 (3.5)	7 (2.3)	6 (1.9)	11 (1.9)	16 (2.7)
Missing data during window but on study	0	0	0	0	0	0

\* Adjusted for baseline stratification factors.

<sup>†</sup> Includes subjects who discontinued for lack of efficacy, discontinued while not suppressed.

N=Number of subjects in each treatment group, CI=confidence interval, CAR=current antiretroviral regimen, RPV=rilpivirine, CAB=cabotegravir.

**Table 8 Proportion of subjects with plasma HIV-1 RNA  $\geq$  50 copies/mL at week 48 for key baseline factors (Snapshot outcomes)**

Baseline factors		Pooled data from FLAIR and ATLAS	
		RPV+CAB N=591 n/N (%)	CAR N=591 n/N (%)
Baseline CD4+ (cells/ mm <sup>3</sup> )	< 350	0/42	2/54 (3.7)
	$\geq$ 350 to < 500	5/120 (4.2)	0/117
	$\geq$ 500	6/429 (1.4)	8/420 (1.9)
Gender	Male	6/429 (1.4)	9/423 (2.1)
	Female	5/162 (3.1)	1/168 (0.6)
Race	White	9/430 (2.1)	7/408 (1.7)
	Black African/American	2/109 (1.8)	3/133 (2.3)
	Asian/Other	0/52	0/48
BMI	< 30 kg/m <sup>2</sup>	6/491 (1.2)	8/488 (1.6)
	$\geq$ 30 kg/m <sup>2</sup>	5/100 (5.0)	2/103 (1.9)
Age (years)	< 50	9/492 (1.8)	8/466 (1.7)
	$\geq$ 50	2/99 (2.0)	2/125 (1.6)
Baseline antiviral therapy at randomisation	PI	1/51 (2.0)	0/54
	INI	6/385 (1.6)	9/382 (2.4)
	NNRTI	4/155 (2.6)	1/155 (0.6)

BMI=body mass index, PI=Protease inhibitor, INI=Integrase inhibitor, NNRTI=non-nucleoside reverse transcriptase inhibitor, RPV=rilpivirine, CAB=cabotegravir, CAR=current antiretroviral regimen

In the FLAIR and ATLAS studies, treatment differences across baseline characteristics (CD4+ count, gender, age, race, BMI, baseline third agent treatment class) were comparable.

In the FLAIR study at 96 Weeks, the results remained consistent with the results at 48 Weeks. The proportion of subjects having plasma HIV-1 RNA  $\geq$  50 c/mL in rilpivirine plus cabotegravir (n=283) and CAR (n=283) was 3.2% and 3.2% respectively (adjusted treatment difference between REKAMBYS plus cabotegravir and CAR [0.0; 95% CI: -2.9, 2.9]). The proportion of subjects having plasma HIV-1 RNA < 50 c/mL in REKAMBYS plus cabotegravir and CAR was 87% and 89%, respectively (adjusted treatment difference between REKAMBYS plus cabotegravir and CAR [-2.8; 95% CI: -8.2, 2.5]).

#### Every 2 months dosing

##### Patients virologically suppressed (stable on prior ART for at least 6 months)

The efficacy and safety of rilpivirine injection given every 2 months, has been evaluated in one Phase 3b randomised, multicentre, parallel-arm, open-label, non-inferiority study, ATLAS-2M (207966). The primary analysis was conducted after all subjects completed their week 48 visit or discontinued the study prematurely.

In ATLAS-2M, 1045 HIV-1 infected, ART-experienced, virologically suppressed subjects were randomised (1:1) and received a rilpivirine plus cabotegravir injection regimen administered either every 2 months or monthly. Subjects initially on non-cabotegravir/rilpivirine treatment received oral lead-in treatment comprising one rilpivirine tablet (25 mg) plus one cabotegravir tablet (30 mg), daily, for at least 4 weeks. Subjects randomised to monthly rilpivirine injections (month 1: 900 mg injection, month 2 onwards: 600 mg injection) and cabotegravir injections (month 1: 600 mg injection, month 2 onwards: 400 mg injection administered) received treatment for an additional 44 weeks. Subjects randomised to every 2 months rilpivirine injections (900 mg injection at months 1, 2, 4 and every 2 months thereafter) and cabotegravir injections (600 mg injection at months 1, 2, 4 and every 2 months thereafter) received treatment for an additional 44 weeks. Prior to randomisation, 63%, 13% and 24% of subjects received rilpivirine plus cabotegravir for 0 weeks, 1 to 24 weeks and > 24 weeks, respectively.

At baseline, the median age of subjects was 42 years, 27% were female, 27% were non-white, 4% were  $\geq$ 65 years, and 6% had a CD4+ cell count less than 350 cells per mm<sup>3</sup>; these characteristics were similar between the treatment arms.



The primary endpoint in ATLAS-2M was the proportion of subjects with a plasma HIV-1 RNA  $\geq 50$  c/mL at week 48 (snapshot algorithm for the ITT-E population).

In ATLAS-2M, rilpivirine plus cabotegravir administered every 2 months was non-inferior to cabotegravir and rilpivirine administered every month on the proportion of subjects having plasma HIV-1 RNA  $\geq 50$  c/mL (1.7% and 1.0% respectively) at week 48. The adjusted treatment difference between cabotegravir plus rilpivirine administered every 2 months and every month (0.8; 95% CI: -0.6, 2.2) met the non-inferiority criterion (upper bound of the 95% CI below 4%).

**Table 9 Virologic outcomes of randomised treatment of ATLAS-2M at 48 weeks (Snapshot analysis)**

	Every 2 months Dosing (Q8W)	Monthly Dosing (Q4W)
	N=522 (%)	N=523 (%)
HIV-1 RNA $\geq 50$ copies/mL <sup>†</sup>	9 (1.7)	5 (1.0)
Treatment Difference % (95% CI)*	0.8 (-0.6, 2.2)	
HIV-1 RNA < 50 copies/mL	492 (94.3)	489 (93.5)
Treatment Difference % (95% CI)*	0.8 (-2.1, 3.7)	
No virologic data at week 48 window	21 (4.0)	29 (5.5)
Reasons:		
Discontinued study due to AE or death	9 (1.7)	13 (2.5)
Discontinued study for other reasons	12 (2.3)	16 (3.1)
On study but missing data in window	0	0

\* Adjusted for baseline stratification factors.

<sup>†</sup> Includes subjects who discontinued for lack of efficacy, discontinued while not suppressed.

N=Number of subjects in each treatment group, CI=confidence interval, CAR=current antiretroviral regimen.

**Table 10 Proportion of subjects with plasma HIV-1 RNA  $\geq 50$  copies/mL in ATLAS-2M at week 48 for key baseline factors (Snapshot outcomes).**

Baseline factors		Number of HIV-1 RNA $\geq 50$ c/mL/ Total Assessed (%)	
		Every 2 months dosing (Q8W)	Monthly dosing (Q4W)
Baseline CD4+ cell count (cells/mm <sup>3</sup> )	< 350	1/ 35 (2.9)	1/ 27 (3.7)
	350 to < 500	1/ 96 (1.0)	0/ 89
	$\geq 500$	7/391 (1.8)	4/407 (1.0)
Gender	Male	4/385 (1.0)	5/380 (1.3)
	Female	5/137 (3.5)	0/143
Race	White	5/370 (1.4)	5/393 (1.3)
	Non-White	4/152 (2.6)	0/130
	Black/African American	4/101 (4.0)	0/ 90
	Non-Black/African American	5/421 (1.2)	5/421 (1.2)
BMI	< 30 kg/m <sup>2</sup>	3/409 (0.7)	3/425 (0.7)
	$\geq 30$ kg/m <sup>2</sup>	6/113 (5.3)	2/98 (2.0)
Age (years)	< 35	4/137 (2.9)	1/145 (0.7)
	35 to < 50	3/242 (1.2)	2/239 (0.8)
	$\geq 50$	2/143 (1.4)	2/139 (1.4)
Prior exposure CAB/RPV	None	5/327 (1.5)	5/327 (1.5)
	1-24 weeks	3/69 (4.3)	0/68

	> 24 weeks	1/126 (0.8)	0/128
--	------------	-------------	-------

BMI=body mass index, CAB=cabotegravir, RPV=rilpivirine

In the ATLAS-2M study, treatment differences on the primary endpoint across baseline characteristics (CD4+ lymphocyte count, gender, race, BMI, age and prior exposure to cabotegravir/rilpivirine) were not clinically meaningful.

The efficacy results at Week 96 are consistent with the results of the primary endpoint at Week 48. Rilpivirine plus cabotegravir injections administered every 2 months is non-inferior to rilpivirine and cabotegravir administered every month. The proportion of subjects having plasma HIV-1 RNA  $\geq 50$  c/mL at Week 96 in rilpivirine plus cabotegravir every 2 months dosing (n=522) and rilpivirine plus cabotegravir monthly dosing (n=523) was 2.1% and 1.1% respectively (adjusted treatment difference between rilpivirine plus cabotegravir every 2 months dosing and monthly dosing [1.0; 95% CI: -0.6, 2.5]). The proportion of subjects having plasma HIV-1 RNA  $< 50$  c/mL at Week 96 in rilpivirine plus cabotegravir every 2 months dosing and rilpivirine plus cabotegravir monthly dosing was 91% and 90.2% respectively (adjusted treatment difference between rilpivirine plus cabotegravir every 2 months dosing and monthly dosing [0.8; 95% CI: -2.8, 4.3]).

The efficacy results at Week 152 are consistent with the results of the primary endpoint at Week 48 and at Week 96. Rilpivirine plus cabotegravir injections administered every 2 months is non-inferior to rilpivirine and cabotegravir administered every month. In an ITT analysis, the proportion of subjects having plasma HIV-1 RNA  $\geq 50$  c/mL at Week 152 in rilpivirine plus cabotegravir every 2 months dosing (n=522) and rilpivirine plus cabotegravir monthly dosing (n=523) was 2.7% and 1.0% respectively (adjusted treatment difference between rilpivirine plus cabotegravir every 2 months dosing and monthly dosing [1.7; 95% CI: 0.1, 3.3]). In an ITT analysis, the proportion of subjects having plasma HIV-1 RNA  $< 50$  c/mL at Week 152 in rilpivirine plus cabotegravir every 2 months dosing and rilpivirine plus cabotegravir monthly dosing was 87% and 86% respectively (adjusted treatment difference between rilpivirine plus cabotegravir every 2 months dosing and monthly dosing [1.5; 95% CI: -2.6, 5.6]).

#### Post-hoc analyses

Multivariable analyses of pooled Phase 3 studies (ATLAS through 96 weeks, FLAIR through 124 weeks, ATLAS-2M through 152 weeks) examined the influence of various factors on the risk of CVF. The baseline factors analysis (BFA) examined baseline viral and participants characteristics and dosing regimen; and the multivariable analysis (MVA) included the baseline factors and incorporated post-baseline predicted plasma drug concentrations on CVF using regression modelling with a variable selection procedure. Following a total of 4291 person-years, the unadjusted CVF incidence rate was 0.54 per 100 person-years; 23 CVFs were reported (1.4% of 1651 individuals in these studies).

The BFA demonstrated rilpivirine resistance mutations (incidence rate ratio IRR=21.65,  $p < 0.0001$ ), HIV-1 subtype A6/A1 (IRR=12.87,  $p < 0.0001$ ), and body mass index IRR=1.09 per 1 unit increase,  $p = 0.04$ ; IRR=3.97 of  $\geq 30$  kg/m<sup>2</sup>,  $p = 0.01$ ) were associated with CVF. Other variables including Q4W or Q8W dosing, female gender, or CAB/INSTI resistance mutations had no significant association with CVF. A combination of at least 2 of the following key baseline factors was associated with an increased risk of CVF: rilpivirine resistance associated mutations, HIV-1 subtype A6/A1, or BMI  $\geq 30$  kg/m<sup>2</sup> (Table 11).

**Table 11 Week 48 Outcomes by Presence of Key Baseline Factors of rilpivirine resistance associated mutations, HIV-1 Subtype A6/A1<sup>1</sup> and BMI  $\geq 30$  kg/m<sup>2</sup>**

Baseline Factors (number)	Virologic Successes <sup>2</sup>	Confirmed Virologic Failure (%) <sup>3</sup>
0	844/970 (87.0)	4/970 (0.4)
1	343/404 (84.9)	8/404 (2.0) <sup>4</sup>
$\geq 2$	44/57 (77.2)	11/57 (19.3) <sup>5</sup>
<b>TOTAL</b> (95% Confidence Interval)	1231/1431 (86/0) (84.1%, 87.8%)	23/1431 (1.6) <sup>6</sup> (1.0%, 2.4%)

<sup>1</sup> HIV-1 subtype A1 or A6 classification based on Los Alamos National Library panel from HIV Sequence database (June 2020)

<sup>2</sup> Based on the FDA Snapshot algorithm of RNA  $< 50$  copies/mL at Week 48 for ATLAS, at Week 124 for FLAIR, at Week 152 for ATLAS-2M.

- 3 Defined as two consecutive measurements of HIV RNA  $\geq 200$  copies/mL.  
 4 Positive Predictive Value (PPV) <1%; Negative Predictive Value (NPV) 98.5%; sensitivity 34.8%; specificity 71.9%  
 5 PPV 19.3%; NPV 99.1%; sensitivity 47.8%; specificity 96.7%  
 6 Analysis dataset with all non-missing covariates for baseline factors (out of a total of 1651 individuals).

In patients with at least two of these risk factors, the proportion of subjects who had a CVF was higher than observed in patients with none or one risk factor, with CVF identified in 6/24 patients [25.0%, 95% CI (9.8%, 46.7%)] treated with the every 2 months dosing regimen and 5/33 patients [15.2%, 95% CI (5.1%, 31.9%)] treated with the monthly dosing regimen.

## 5.2 Pharmacokinetic properties

The pharmacokinetic properties of REKAMBYS have been evaluated in healthy and HIV-1 infected adults.

**Table 12: Population pharmacokinetic parameters following once-daily oral rilpivirine and following initiation and monthly or every two months continuation intramuscular injections of REKAMBYS**

Dosing phase	Dose regimen	Geometric mean (5 <sup>th</sup> ; 95 <sup>th</sup> Percentile)		
		AUC <sub>(0-tau)</sub> <sup>b</sup> (ng•h/mL)	C <sub>max</sub> (ng/mL)	C <sub>tau</sub> <sup>b</sup> (ng/mL)
Oral Lead-In <sup>c</sup>	25 mg once daily	2,083 (1,125; 3,748)	116 (48.6; 244)	79.4 (31.8; 177)
Initial Injection <sup>a,d</sup>	900 mg IM initial dose	44,854 (21,712; 87,528)	144 (93.9; 220)	42.0 (21.8; 78.9)
Monthly Injection <sup>a,c</sup>	600 mg IM monthly	67,703 (39,029; 117,472)	120 (68.2; 208)	84.9 (49.4; 146)
Every 2 months Injection <sup>a,c</sup>	900 mg IM every 2 months	127,031 (74,845; 211,644)	133 (77.8; 223)	65.6 (36.9; 113)

- a. Based on individual post-hoc estimates from rilpivirine IM population pharmacokinetic model (pooled data FLAIR, ATLAS and ATLAS-2M).  
 b. tau is dosing interval: 24 hours for oral; 1 or 2 months for monthly or every 2 months IM injections.  
 c. For oral rilpivirine, C<sub>tau</sub> represents observed pooled data FLAIR, ATLAS and ATLAS-2M, AUC<sub>(0-tau)</sub> and C<sub>max</sub> represent pharmacokinetic data from oral rilpivirine Phase 3 studies  
 d. Initial injection C<sub>max</sub> primarily reflects oral dosing because the initial injection was administered on the same day as the last oral dose.  
 e. Week 48 data.

### Absorption

Rilpivirine prolonged-release injection exhibits absorption rate-limited kinetics (i.e., flip-flop pharmacokinetics) resulting from slow absorption from the gluteal muscle into the systemic circulation resulting in sustained rilpivirine plasma concentrations.

Following a single intramuscular dose, rilpivirine plasma concentrations are detectable the first day and gradually rise to reach maximum plasma concentrations after a median of 3-4 days. Rilpivirine has been detected in plasma up to 52 weeks or longer after administration of a single dose of REKAMBYS. After 1 year of monthly or every 2 months injections, approximately 80% of the rilpivirine pharmacokinetic steady-state exposure is reached.

Plasma rilpivirine exposure increases in proportion or slightly less than in proportion to dose following single and repeat IM injections of doses ranging from 300 to 1200 mg.

### Distribution

Rilpivirine is approximately 99.7% bound to plasma proteins *in vitro*, primarily to albumin. Based on population pharmacokinetics analysis, the typical apparent volume of the central compartment (V<sub>c</sub>/F) for rilpivirine after IM administration was estimated to be 132 L, reflecting a moderate distribution to

peripheral tissues.

Rilpivirine is present in cerebrospinal fluid (CSF). In HIV-1-infected subjects receiving a regimen of rilpivirine injection plus cabotegravir injection, the median rilpivirine CSF to plasma concentration ratio (n=16) was 1.07 to 1.32% (range: not quantifiable to 1.69%). Consistent with therapeutic rilpivirine concentrations in the CSF, CSF HIV-1 RNA (n=16) was < 50 c/mL in 100% and < 2 c/mL in 15/16 (94%) of subjects. At the same time point, plasma HIV-1 RNA (n=18) was < 50 c/mL in 100% and < 2 c/mL in 12/18 (66.7%) of subjects.

### Biotransformation

*In vitro* experiments indicate that rilpivirine primarily undergoes oxidative metabolism mediated by the cytochrome P450 (CYP) 3A system.

### Elimination

The mean apparent half-life of rilpivirine following REKAMBYS administration is absorption rate-limited and was estimated to be 13-28 weeks.

The apparent plasma clearance (CL/F) of rilpivirine was estimated to be 5.08 L/h.

After single dose administration of oral <sup>14</sup>C-rilpivirine, on average 85% and 6.1% of the radioactivity could be retrieved in faeces and urine, respectively. In faeces, unchanged rilpivirine accounted for on average 25% of the administered dose. Only trace amounts of unchanged rilpivirine (< 1% of dose) were detected in urine.

### Special patient populations

#### *Gender*

No clinically relevant differences in the rilpivirine exposure after intramuscular (IM) administration have been observed between men and women.

#### *Race*

No clinically relevant effect of race on the rilpivirine exposure after intramuscular administration has been observed.

#### *BMI*

No clinically relevant effect of BMI on the rilpivirine exposure after intramuscular administration has been observed.

#### *Elderly*

No clinically relevant effect of age on the rilpivirine exposure after intramuscular administration has been observed. Pharmacokinetic data for rilpivirine in subjects of > 65 years old are limited.

#### *Renal impairment*

The pharmacokinetics of rilpivirine have not been studied in patients with renal insufficiency. Renal elimination of rilpivirine is negligible. No dose adjustment is needed for patients with mild or moderate renal impairment. In patients with severe renal impairment or end-stage renal disease, REKAMBYS should be used with caution, as plasma concentrations may be increased due to alteration of drug absorption, distribution and/or metabolism secondary to renal dysfunction. In patients with severe renal impairment or end-stage renal disease, the combination of REKAMBYS with a strong CYP3A inhibitor should only be used if the benefit outweighs the risk. As rilpivirine is highly bound to plasma proteins, it is unlikely that it will be significantly removed by haemodialysis or peritoneal dialysis (see section 4.2).

#### *Hepatic impairment*

Rilpivirine is primarily metabolised and eliminated by the liver. In a study comparing 8 patients with mild hepatic impairment (Child-Pugh score A) to 8 matched controls, and 8 patients with moderate

hepatic impairment (Child-Pugh score B) to 8 matched controls, the multiple dose exposure of oral rilpivirine was 47% higher in patients with mild hepatic impairment and 5% higher in patients with moderate hepatic impairment. However, it may not be excluded that the pharmacologically active, unbound, rilpivirine exposure is significantly increased in moderate hepatic impairment. No dose adjustment is suggested but caution is advised in patients with moderate hepatic impairment. REKAMBYS has not been studied in patients with severe hepatic impairment (Child-Pugh score C). Therefore, REKAMBYS is not recommended in patients with severe hepatic impairment (see section 4.2).

#### *HBV/HCV Co-infected Patients*

Population pharmacokinetic analysis indicated that hepatitis B and/or C virus co-infection had no clinically relevant effect on the rilpivirine exposure after oral rilpivirine intake.

#### *Paediatric Patients*

The pharmacokinetics of rilpivirine in children and adolescents aged < 18 years have not been established with REKAMBYS.

### **5.3 Preclinical safety data**

All studies were performed with rilpivirine for oral use except for the studies on local tolerance with REKAMBYS injections.

#### Repeated dose toxicity

Liver toxicity associated with liver enzyme induction was observed in rodents. In dogs, cholestasis-like effects were noted.

#### Reproductive toxicology studies

Studies in animals have shown no evidence of relevant embryonic or foetal toxicity or an effect on reproductive function. There was no teratogenicity with oral rilpivirine in rats and rabbits. The exposures at the embryo-foetal No Observed Adverse Effects Levels (NOAELs) in rats and rabbits were respectively  $\geq 12$  times and  $\geq 57$  times the exposure in humans at the maximum recommended human daily dose of 25 mg once daily in HIV-1 infected patients or 600 mg or 900 mg intramuscular injection dose of rilpivirine long-acting injectable suspension.

#### Carcinogenesis and mutagenesis

Oral rilpivirine was evaluated for carcinogenic potential by oral gavage administration to mice and rats up to 104 weeks. At the lowest tested doses in the carcinogenicity studies, the systemic exposures (based on AUC) to rilpivirine were  $\geq 17$  times (mice) and  $\geq 2$  times (rats) the exposure in humans at the maximum recommended human daily dose of 25 mg once daily in HIV-1 infected patients or 600 mg or 900 mg intramuscular injection dose of rilpivirine long-acting injectable suspension. In rats, there were no drug-related neoplasms. In mice, rilpivirine was positive for hepatocellular neoplasms in both males and females. The observed hepatocellular findings in mice may be rodent-specific.

Rilpivirine has tested negative in the absence and presence of a metabolic activation system in the *in vitro* Ames reverse mutation assay and the *in vitro* clastogenicity mouse lymphoma assay. Rilpivirine did not induce chromosomal damage in the *in vivo* micronucleus test in mice.

#### Local tolerance for REKAMBYS

After long-term repeated IM administration of REKAMBYS in dogs and minipigs, slight, short-lasting (i.e., 1-4 days in minipigs) erythema was observed, and white deposits were noted at the injection sites at necropsy, accompanied by swelling and discolouration of draining lymph nodes. Microscopic examination showed macrophage infiltration and eosinophilic deposits at the injection sites. A macrophage infiltration response was also noted in the draining/regional lymph nodes. These findings were considered to be a reaction to the deposited material rather than a manifestation of local irritation.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

poloxamer 338  
glucose monohydrate  
sodium dihydrogen phosphate monohydrate  
citric acid monohydrate  
sodium hydroxide (to adjust pH)  
water for injections

### **6.2 Incompatibilities**

This medicinal product must not be mixed with other medicinal products or diluents.

### **6.3 Shelf life**

The expiry date of the product is indicated on the packaging materials.

Chemical and physical in-use stability has been demonstrated for 6 hours at 25°C.

Once the suspension has been drawn into the syringe, the injection should be administered as soon as possible, but may remain in the syringe for up to 2 hours. If 2 hours are exceeded, the medicine, syringe, and needle must be discarded.

### **6.4 Special precautions for storage**

Store in a refrigerator (2°C - 8°C).  
Do not freeze.

Prior to administration, the vial should be brought to room temperature (not to exceed 25°C). The vial may remain in the carton at room temperature for up to 6 hours; do not put back into the refrigerator. If not used within 6 hours, the vial must be discarded (refer to section 6.3).

### **6.5 Nature and contents of container**

Type I glass vial.

#### 600 mg pack

Each pack contains one clear 4-mL glass vial, with a butyl elastomer stopper and an aluminium overseal with a plastic flip-off button, 1 syringe (0.2 mL graduation), 1 vial adaptor and 1 needle for injection (23 gauge, 1½ inch).

#### 900 mg pack

Each pack contains one clear 4-mL glass vial, with a butyl elastomer stopper and an aluminium overseal with a plastic flip-off button, 1 syringe (0.2 mL graduation), 1 vial adaptor and 1 needle for injection (23 gauge, 1½ inch).

### **6.6 Special precautions for disposal and other handling**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Full instructions for use and handling of REKAMBYS are provided in the package leaflet (see Instructions for Use).

**7. MARKETING AUTHORISATION HOLDER**

J-C Health Care Ltd., Kibbutz Shefayim 6099000, Israel.

**8. MARKETING AUTHORISATION NUMBER**

170-12-36949-99

**9. MANUFACTURER**

Cilag AG, Hochstrasse 201, 8200 Schaffhausen Switzerland.

**Revised in September 2023 according to the MOH guidelines.**

The following information is intended for medical or healthcare professionals only and should be read by the medical or healthcare professional in conjunction with the full prescribing information (Summary of Product Characteristics).

### REKAMBYS 2 mL injection Instructions for use:

#### Overview

A complete dose requires two injections:

2 mL of cabotegravir and 2 mL of rilpivirine.

Cabotegravir and rilpivirine are suspensions that do not need further dilution or reconstitution. The preparation steps for both medicines are the same.

Cabotegravir and rilpivirine are for intramuscular use only. Both injections must be administered to the gluteal sites. The administration order is not important.

**Note:** The ventrogluteal site is recommended.




#### Storage information

• Store in refrigerator at 2°C to 8°C.


**Do not freeze.**

#### Rilpivirine vial




**Vial cap**  
(Rubber stopper under cap)


#### Vial adaptor



#### Syringe



#### Injection needle



#### Your pack contains

- 1 vial of rilpivirine
- 1 vial adaptor
- 1 syringe
- 1 injection needle (23 gauge, 1½ inch)  
Consider the patient's build and use medical judgment to select an appropriate injection needle length.




## You will also need

- Non-sterile gloves
- 2 alcohol swabs
- 2 gauze pads
- A suitable sharps container
- 1 cabotegravir 2 mL or 3 mL pack
- Make sure to have the cabotegravir pack close by before starting.

## Preparation

### 1. Inspect vial

Check expiry date and medicine



- Check that the expiry date has not passed.
- Inspect the vials immediately. If you can see foreign matter, do not use the product.

**Do not** use if the expiry date has passed.

### 2. Wait 15 minutes




Wait 15 minutes



- Wait at least 15 minutes before you are ready to give the injection to allow the medicine to come to room temperature.

### 3. Shake vigorously

10 secs



- Hold the vial firmly and vigorously shake for a full 10 seconds as shown.
- Invert the vial and check the resuspension. It should look uniform. If the suspension is not uniform, shake the vial again.
- It is also normal to see small air bubbles.


#### 4. Remove vial cap



- Remove the cap from the vial.
- Wipe the rubber stopper with an alcohol swab.

**Do not** allow anything to touch the rubber stopper after wiping it.


#### 5. Peel open vial adaptor



- Peel off the paper backing from the vial adaptor packaging.


**Note:** Keep the adaptor in place in its packaging for the next step.

#### 6. Attach vial adaptor




- Press the vial adaptor straight down onto the vial using the packaging, as shown. The vial adaptor should snap securely into place.
- When you are ready, lift off the vial adaptor packaging as shown.

#### 7. Prepare syringe




- Remove the syringe from its packaging.
- Draw 1 mL of air into the syringe. This will make it easier to draw up the liquid later.

## 8. Attach syringe




- Hold the vial adaptor and vial firmly, as shown.
- Screw the syringe firmly onto the vial adaptor.
- Press the plunger all the way down to push the air into the vial.

## 9. Slowly draw up dose



- Invert the syringe and vial, and slowly withdraw as much of the liquid as possible into the syringe. There might be more liquid than dose amount.


## 10. Unscrew syringe



- Screw the syringe off the vial adaptor, holding the vial adaptor as shown.

**Note:** Keep the syringe upright to avoid leakage. Check that the suspension looks uniform and milky white.


## 11. Attach needle



- Peel open the needle packaging part way to expose the needle base.
- Keeping the syringe upright, firmly twist the syringe onto the needle.
- Remove the needle packaging from the needle.

## Injection

## 12. Prepare injection site



Injections must be administered to the gluteal sites. Select from the following areas for the injection:

- Ventrogluteal (recommended)
- Dorsogluteal (upper outer quadrant)


**Note:** For gluteal intramuscular use only.  
**Do not** inject intravenously.

## 13. Remove cap



- Fold the needle guard away from the needle.
- Pull off the injection needle cap.


## 14. Remove extra liquid



- Hold the syringe with the needle pointing up. Press the plunger to the 2 mL dose to remove extra liquid and any air bubbles.

**Note:** Clean the injection site with an alcohol swab. Allow the skin to air dry before continuing.


## 15. Stretch skin



Use the z-track injection technique to minimise medicine leakage from the injection site.


- Firmly drag the skin covering the injection site, displacing it by about an inch (2.5 cm).
- Keep it held in this position for the injection.

## 16. Insert needle




- Insert the needle to its full depth, or deep enough to reach the muscle.

## 17. Inject dose



- Still holding the skin stretched – slowly press the plunger all the way down.
- Ensure the syringe is empty.
- Withdraw the needle and release the stretched skin immediately.


## 18. Assess the injection site



- Apply pressure to the injection site using a gauze.
- A small bandage may be used if a bleed occurs.

**Do not** massage the area.


## 19. Make needle safe



- Fold the needle guard over the needle.
- Gently apply pressure using a hard surface to lock the needle guard in place.
- The needle guard will make a click when it locks.

## After injection

## 20. Dispose safely



- Dispose of used needles, syringes, vials and vial adaptors according to local health and safety laws.

## Repeat for 2nd medicine



**Repeat all steps  
for 2nd medicine**

If you have not yet injected both medicines, use the steps for preparation and injection for Cabotegravir which has its own specific Instructions for Use.

## Questions and Answers

### 1. How long can the medicine be left out of the refrigerator?

It is best to inject the medicine as soon as it reaches room temperature. However, the vial may sit in the carton at room temperature (maximum temperature of 25°C) for up to 6 hours; do not put back into the refrigerator. If not used within 6 hours, the vial must be discarded.

### 2. How long can the medicine be left in the syringe?

It is best to inject the (room temperature) medicine as soon as possible after drawing it up. However, the medicine can remain in the syringe for up to 2 hours before injecting. If 2 hours are exceeded, the medicine, syringe and needle must be discarded.

### 3. Why do I need to inject air into the vial?

Injecting 1 mL of air into the vial makes it easier to draw up the dose into the syringe. Without the air, some liquid may flow back into the vial unintentionally, leaving less than intended in the syringe.

### 4. Does the order in which I give the medicines matter?

No, the order is unimportant.

### 5. Is it safe to warm the vial up to room temperature more quickly?

It is best to let the vial come to room temperature naturally. However, you can use the warmth of your hands to speed up the warm up time, but make sure the vial does not get above 25°C.

Do not use any other heating methods.

### 6. Why is the ventrogluteal administration approach recommended?

The ventrogluteal approach, into the gluteus medius muscle, is recommended because it is located away from major nerves and blood vessels. A dorso-gluteal approach, into the gluteus maximus muscle, is acceptable, if preferred by the healthcare professional. The injection should not be administered in any other site.

The following information is intended for medical or healthcare professionals only and should be read by the medical or healthcare professional in conjunction with the full prescribing information (Summary of Product Characteristics).

### REKAMBYS 3 mL injection Instructions for use:

#### Overview

A complete dose requires two injections:

3 mL of cabotegravir and 3 mL of rilpivirine.

Cabotegravir and rilpivirine are suspensions that do not need further dilution or reconstitution. The preparation steps for both medicines are the same.

Cabotegravir and rilpivirine are for intramuscular use only. Both injections must be administered to the gluteal sites. The administration order is not important.

**Note:** The ventrogluteal site is recommended.




#### Storage information

• Store in refrigerator at 2°C to 8°C.

**Do not** freeze.

#### Rilpivirine vial




**Vial cap**  
(Rubber stopper under cap)

#### Vial adaptor




#### Syringe



**Plunger**

#### Injection needle



**Needle guard**

**Needle cap**

#### Your pack contains

- 1 vial of rilpivirine
- 1 vial adaptor
- 1 syringe
- 1 injection needle (23 gauge, 1½ inch)

Consider the patient's build and use medical judgment to select an appropriate injection needle length.




## You will also need

- Non-sterile gloves
- 2 alcohol swabs
- 2 gauze pads
- A suitable sharps container
- 1 cabotegravir 2 mL or 3 mL pack
- Make sure to have the cabotegravir pack close by before starting.

## Preparation

### 1. Inspect vial

Check expiry date and medicine



- Check that the expiry date has not passed.
- Inspect the vials immediately. If you can see foreign matter, do not use the product.

**Do not use if the expiry date has passed.**

### 2. Wait 15 minutes




Wait 15 minutes



- Wait at least 15 minutes before you are ready to give the injection to allow the medicine to come to room temperature.


### 3. Shake vigorously

10 secs



- Hold the vial firmly and vigorously shake for a full 10 seconds as shown.
- Invert the vial and check the resuspension. It should look uniform. If the suspension is not uniform, shake the vial again.
- It is also normal to see small air bubbles.


#### 4. Remove vial cap



- Remove the cap from the vial.
- Wipe the rubber stopper with an alcohol swab.

**Do not** allow anything to touch the rubber stopper after wiping it.


#### 5. Peel open vial adaptor



- Peel off the paper backing from the vial adaptor packaging.


**Note:** Keep the adaptor in place in its packaging for the next step.

#### 6. Attach vial adaptor




- Press the vial adaptor straight down onto the vial using the packaging, as shown. The vial adaptor should snap securely into place.
- When you are ready, lift off the vial adaptor packaging as shown.

#### 7. Prepare syringe




- Remove the syringe from its packaging.
- Draw 1 mL of air into the syringe. This will make it easier to draw up the liquid later.

## 8. Attach syringe




- Hold the vial adaptor and vial firmly, as shown.
- Screw the syringe firmly onto the vial adaptor.
- Press the plunger all the way down to push the air into the vial.

## 9. Slowly draw up dose



- Invert the syringe and vial, and slowly withdraw as much of the liquid as possible into the syringe. There might be more liquid than dose amount.


## 10. Unscrew syringe



- Screw the syringe off the vial adaptor, holding the vial adaptor as shown.

**Note:** Keep the syringe upright to avoid leakage. Check that the suspension looks uniform and milky white.


### 11. Attach needle



- Peel open the needle packaging part way to expose the needle base.
- Keeping the syringe upright, firmly twist the syringe onto the needle.
- Remove the needle packaging from the needle.

## Injection

### 12. Prepare injection site




Injections must be administered to the gluteal sites. Select from the following areas for the injection:

- Ventrogluteal (recommended)
- Dorsogluteal (upper outer quadrant)


**Note:** For gluteal intramuscular use only.  
**Do not** inject intravenously.

### 13. Remove cap



- Fold the needle guard away from the needle.
- Pull off the injection needle cap.


### 14. Remove extra liquid



- Hold the syringe with the needle pointing up. Press the plunger to the 3 mL dose to remove extra liquid and any air bubbles.

**Note:** Clean the injection site with an alcohol swab. Allow the skin to air dry before continuing.


## 15. Stretch skin



Use the z-track injection technique to minimise medicine leakage from the injection site.


- Firmly drag the skin covering the injection site, displacing it by about an inch (2.5 cm).
- Keep it held in this position for the injection.

## 16. Insert needle



- Insert the needle to its full depth, or deep enough to reach the muscle.

## 17. Inject dose



- Still holding the skin stretched – slowly press the plunger all the way down.
- Ensure the syringe is empty.
- Withdraw the needle and release the stretched skin immediately.


## 18. Assess the injection site



- Apply pressure to the injection site using a gauze.
- A small bandage may be used if a bleed occurs.

**Do not** massage the area.


## 19. Make needle safe



- Fold the needle guard over the needle.
- Gently apply pressure using a hard surface to lock the needle guard in place.
- The needle guard will make a click when it locks.

## After injection

## 20. Dispose safely



- Dispose of used needles, syringes, vials and vial adaptors according to local health and safety laws.

## Repeat for 2nd medicine



**Repeat all steps  
for 2nd medicine**

If you have not yet injected both medicines, use the steps for preparation and injection for Cabotegravir which has its own specific Instructions for Use.

## Questions and Answers

### 1. How long can the medicine be left out of the refrigerator?

It is best to inject the medicine as soon as it reaches room temperature. However, the vial may sit in the carton at room temperature (maximum temperature of 25°C) for up to 6 hours; do not put back into the refrigerator. If not used within 6 hours, the vial must be discarded.

### 2. How long can the medicine be left in the syringe?

It is best to inject the (room temperature) medicine as soon as possible after drawing it up. However, the medicine can remain in the syringe for up to 2 hours before injecting. If 2 hours are exceeded, the medicine, syringe and needle must be discarded.

### 3. Why do I need to inject air into the vial?

Injecting 1 mL of air into the vial makes it easier to draw up the dose into the syringe. Without the air, some liquid may flow back into the vial unintentionally, leaving less than intended in the syringe.

### 4. Does the order in which I give the medicines matter?

No, the order is unimportant.

### 5. Is it safe to warm the vial up to room temperature more quickly?

It is best to let the vial come to room temperature naturally. However, you can use the warmth of your hands to speed up the warm up time, but make sure the vial does not get above 25°C.

Do not use any other heating methods.

### 6. Why is the ventrogluteal administration approach recommended?

The ventrogluteal approach, into the gluteus medius muscle, is recommended because it is located away from major nerves and blood vessels. A dorso-gluteal approach, into the gluteus maximus muscle, is acceptable, if preferred by the healthcare professional. The injection should not be administered in any other site.